Clinical Trials

Find a Trial

Trial Results

20 protocol(s) meet the specified criteria
201610019OPEN TO ACCRUAL
A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
BR-076OPEN TO ACCRUAL
A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 ( pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
E1Z11OPEN TO ACCRUAL
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2112OPEN TO ACCRUAL
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
EAI142OPEN TO ACCRUAL
Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients w/ Newly Diagnosed Metastatic Breast Cancer
EAY131-C1/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
EAY131-C2/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
EAY131-L/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
EAY131-M/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
EAY131-Z1C/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1E/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
EAY131/MATCHOPEN TO ACCRUAL
Molecular Analysis for Therapy Choice (MATCH)
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
IUSCC-0555OPEN TO ACCRUAL
Inhibiting fatty acid synthase to improve efficacy of neoadjuvant chemotherapy.
IUSCC-0590OPEN TO ACCRUAL
iMETX (Individualized Metabolic RX): a pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors
IUSCC-0613OPEN TO ACCRUAL
An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
PRE0109OPEN TO ACCRUAL
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer [AFT-05]
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS